Maplight Therapeutics (MPLT)Director bought ~$186K

~$186K

Approx. value · 11K sh @ $17.48

11K

Holds after · shares reported

Traded

Feb 18, 2026

Filed

Feb 20, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 9, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. Jan 28, 2026Insider · 1 personInsiders: 2 sales (~$122K)
3. Jan 29, 2026InsiderDirector sold ~$394K of MPLT shares in the open market
4. Jan 30, 2026InsiderDirector sold ~$120K of MPLT shares in the open market
5. Feb 2, 2026InsiderDirector sold ~$127K of MPLT shares in the open market
6. Feb 3, 2026InsiderDirector sold ~$18 of MPLT shares in the open market
7. Feb 10, 2026Insider · 2 peopleInsiders: 1 purchase (~$253K), 1 sale (~$120K)
8. Feb 11, 2026InsiderDirector sold ~$4.3K of MPLT shares in the open market
9. Feb 13, 2026InsiderDirector sold ~$221K of MPLT shares in the open market
10. Feb 18, 2026 · this disclosureInsider · Their first buy on recordDirector purchased ~$186K of MPLT shares in the open market

What came next

1. Feb 19, 2026InsiderDirector purchased ~$78K of MPLT shares in the open market
2. Feb 20, 2026Insider · 2 peopleInsiders: 1 purchase (~$177K), 1 sale (~$40K)
3. Feb 23, 2026Insider · 1 personInsiders: 2 sales (~$207K)
4. Feb 24, 2026InsiderDirector sold ~$13K of MPLT shares in the open market
5. Mar 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
6. Apr 15, 2026Insider · 8 peopleInsiders: 8 sales (~$879K)
7. Apr 16, 2026Insider · 5 peopleInsiders: 10 sales (~$395K)
8. Apr 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the “Board”) of MapLight Therapeutics, Inc. (the “Company”) of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.”
9. Apr 27, 2026Insider · 2 peopleInsiders: 6 sales (~$2.9M)
10. Apr 28, 2026Insider · 1 personInsiders: 2 sales (~$544K)
11. May 4, 2026Insider · 5 peopleInsiders: 20 sales (~$2.1M)
12. May 5, 2026Insider · 4 peopleInsiders: 8 sales (~$1.2M)
13. May 6, 2026Insider · 4 peopleInsiders: 8 sales (~$2.4M)
14. May 11, 2026InsiderOfficer sold ~$7.8K of MPLT shares in the open market
15. May 14, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
16. Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 18, 2026, Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the “Company”), effective immediately, following a review of a human resources violation.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Maplight Therapeutics

For Maplight Therapeutics, OQRO holds 52 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MPLT page.

Other recent filings by George Pavlov, Director

• SEC Form 4 at Maplight Therapeutics (MPLT)Feb 20, 2026
• SEC Form 4 at Maplight Therapeutics (MPLT)Feb 20, 2026

The full history of George Pavlov, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Maplight Therapeutics

• SEC Form 4Sep 18, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Aug 5, 2026
• SEC Form 4Jul 30, 2026
• SEC Form 4Jul 30, 2026

Everything OQRO holds on this company is on its MPLT page.